Abstract
In this study we retrospectively reviewed dupilumab’s efficacy and safety profile in treating elderly patients with atopic dermatitis (AD) and explored the predictive indicators for its efficacy. After analysing data from 181 patients we found that dupilumab appears to be effective and well-tolerated in treating AD among elderly patients. More importantly, we found that disease severity and early response to dupilumab are associated with complete remission at week 24 and may be used as potential predictive indicators for dupilumab’s efficacy.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call